Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,696 signal articles · 54 in last 24h · 156,275 total before filter · latest 34m ago
54last 24h
853last 7d
151● bullish (7d)
86● bearish (7d)
214publishers
AllMacro190Earnings117M&A122Regulatory20Product19Analyst22
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
FTAI Aviation (FTAI) Reported Mixed Earnings And Raised Its Dividend, Is It A Bargain?
Simply Wall St.59d agoneutral
FTAI Aviation (FTAI) Reported Mixed Earnings And Raised Its Dividend, Is It A Bargain?

FTAI Aviation (FTAI) stock was in focus after the company reported second quarter 2026 earnings, an increased ordinary dividend, and new contract and partnership announcements that drew close attention from income and growth focused investors. See our latest analysis for FTAI Aviation. FTAI Aviation’s share price has pulled back sharply in the near term, with a 1 day share price return down 7.11% and a 30 day share price return down 25.13%, even though the 1 year total shareholder return is...

Is Generac Holdings (GNRC) Undervalued On Its Q2 Earnings Beat And Reaffirmed Outlook?
Simply Wall St.59d agobullish
Is Generac Holdings (GNRC) Undervalued On Its Q2 Earnings Beat And Reaffirmed Outlook?

Generac Holdings (GNRC) is back in focus after reporting second quarter 2026 results that outpaced profit expectations, alongside a reaffirmed full year net sales growth outlook in the mid to high teens range. See our latest analysis for Generac Holdings. Despite the strong Q2 earnings beat and reaffirmed guidance, Generac Holdings shares have come under pressure recently, with a 30-day share price return down 31.23% and a 90-day share price return down 24.70%. Even so, the year to date share...

Sanofi Q2 Earnings Call Highlights
MarketBeat59d agoneutral
Sanofi Q2 Earnings Call Highlights

Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongo